Tempus AI, Inc. (TEM)
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with distinct niche. Tempus is focused on advancing precision medicine through artificial intelligence.
Tempus AI: An Attractive Entry Point At Current Prices
Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, reinforced by the Ambry Genetics acquisition and expanding pharma partnerships. Diagnostics revenue more than doubled YoY, while high-margin data and applications segments drive improving blended margins and record $1.1B TCV.
Tempus AI Reinforces Market Position With Collaborations in 2026
TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.
Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story
Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.
Tempus AI, Inc. $TEM Shares Bought by Bamco Inc. NY
Bamco Inc. NY raised its holdings in shares of Tempus AI, Inc. (NASDAQ: TEM) by 53.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,250 shares of the company's stock after buying an additional 92,007 shares during the quarter.
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?
TEM eyes 2026 growth by scaling diagnostics, MRD testing and AI-driven clinical apps as revenues surge 83%, though valuation concerns temper the outlook.
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth?
Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.
